Medexus Pharmaceuticals (MDP.T) announced today that it has completed enrollment in its Phase 4 clinical trial of IXINITY®, targeting label expansion for pediatric hemophilia B. We are hopeful that…
Pharmaceuticals
Xeris Pharmaceuticals (XERS.Q) announces today that the U.S. Food and Drug Administration (FDA) has allowed the Investigational New Drug Application (IND) for the Company’s XeriSol™ levothyroxine (XP-8121) for hypothyroidism…
Stock Performance From the chart below it seemed like the Valeo Pharma (“VPH”) shareholders have had quite a wild ride over the last few years. Starting in 2019 the…
Steve Saviuk, president and CEO of Valeo Pharma (VPH.C), talks about the transformative partnerships with international players such as Novartis and members of the Canadian Healthcare Industry, that allow…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
There’s nothing more terrifying than watching a loved one pause, clutch their throat and start gasping for air. The first time it happens provokes the mad scramble, as she…
Fulcrum Therapeutics (FULC.Q) announced positive results today from its ongoing Phase 1 trial with FTX-6058 in healthy adult volunteers. “We are very pleased with the interim results from this…
Axsome Therapeutics (AXSM.Q) announced today that its AXS-05 has met primary and key secondary endpoints in the MERIT (Mechanistic Evaluation of Response in TDR) Phase 2 trial. Additionally, the…
Spectrum Pharmaceuticals (SPPI.Q) announced today that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company’s Biologics License Application (BLA)…
PharmaTher (PHRM.C) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for ketamine in the treatment of Amyotrophic Lateral Sclerosis (ALS), also…